Finerenone (BioDeep_00000839604)
代谢物信息卡片
Finerenone
化学式: C21H22N4O3 (378.1692)
中文名称:
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CCOC1=NC=C(C2=C1C(C(=C(N2)C)C(=O)N)C3=C(C=C(C=C3)C#N)OC)C
InChI: InChI=1S/C21H22N4O3/c1-5-28-21-18-17(14-7-6-13(9-22)8-15(14)27-4)16(20(23)26)12(3)25-19(18)11(2)10-24-21/h6-8,10,17,25H,5H2,1-4H3,(H2,23,26)/t17-/m1/s1
描述信息
C - Cardiovascular system > C03 - Diuretics > C03D - Aldosterone antagonists and other potassium-sparing agents > C03DA - Aldosterone antagonists
C78274 - Agent Affecting Cardiovascular System
同义名列表
1 个代谢物同义名
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
| 亚细胞结构定位 | 关联基因列表 |
|---|
文献列表
- Xiaoming Xu, Jing Feng, Yuying Cui, Pingjiang Li, Jianjun Dong, Lin Liao. Renal effects and safety between Asian and non-Asian chronic kidney disease and type 2 diabetes treated with nonsteroidal mineralocorticoid antagonists.
Journal of diabetes.
2024 Jun; 16(6):e13566. doi:
10.1111/1753-0407.13566. [PMID: 38753662] - Pingjiang Li, Yuying Cui, Xiaoming Xu, Jianjun Dong, Lin Liao. Cardiorenal Benefits of Finerenone in Different Races and Kidney Function in Patients with Chronic Kidney Disease.
Cardiorenal medicine.
2024; 14(1):227-234. doi:
10.1159/000538347. [PMID: 38537621] - Hiddo J L Heerspink, Andreas L Birkenfeld, David Z I Cherney, Helen M Colhoun, Linong Ji, Chantal Mathieu, Per-Henrik Groop, Richard E Pratley, Sylvia E Rosas, Peter Rossing, Jay S Skyler, Katherine R Tuttle, Robert Lawatscheck, Charlie Scott, Robert Edfors, Markus F Scheerer, Peter Kolkhof, Janet B McGill. Rationale and design of a randomised phase III registration trial investigating finerenone in participants with type 1 diabetes and chronic kidney disease: The FINE-ONE trial.
Diabetes research and clinical practice.
2023 Oct; 204(?):110908. doi:
10.1016/j.diabres.2023.110908. [PMID: 37805000] - Janet B McGill, Rajiv Agarwal, Stefan D Anker, George L Bakris, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Andreas L Birkenfeld, Maria L Caramori, Meike Brinker, Amer Joseph, Andrea Lage, Robert Lawatscheck, Charlie Scott, Peter Rossing. Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline.
Diabetes, obesity & metabolism.
2023 06; 25(6):1512-1522. doi:
10.1111/dom.14999. [PMID: 36722675] - Peter Bramlage, Stefanie Lanzinger, Steffen Mühldorfer, Karsten Milek, Anton Gillessen, Roman Veith, Tobias Ohde, Thomas Danne, Reinhard W Holl, Jochen Seufert. An analysis of DPV and DIVE registry patients with chronic kidney disease according to the finerenone phase III clinical trial selection criteria.
Cardiovascular diabetology.
2023 05; 22(1):108. doi:
10.1186/s12933-023-01840-5. [PMID: 37158855] - Peter Rossing, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Andreas L Birkenfeld, Janet B McGill, Sylvia E Rosas, Amer Joseph, Martin Gebel, Luke Roberts, Markus F Scheerer, George L Bakris, Rajiv Agarwal. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.
Diabetes care.
2022 12; 45(12):2991-2998. doi:
10.2337/dc22-0294. [PMID: 35972218] - Roland Heinig, Johannes Nagelschmitz, Stephanie Loewen. Results From Phase I Studies Investigating the Dose Linearity of Finerenone Tablets and the Influence of Food or pH-Modifying Comedications on its Pharmacokinetics in Healthy Male Volunteers.
European journal of drug metabolism and pharmacokinetics.
2022 Jul; 47(4):549-559. doi:
10.1007/s13318-022-00770-z. [PMID: 35612708] - Ralph A DeFronzo, George L Bakris. Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes.
Diabetes, obesity & metabolism.
2022 07; 24(7):1197-1205. doi:
10.1111/dom.14696. [PMID: 35302284] - Sebastiaan Camiel Goulooze, Hiddo J L Heerspink, Martijn van Noort, Nelleke Snelder, Meike Brinker, Joerg Lippert, Thomas Eissing. Dose-Exposure-Response Analysis of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone on UACR and eGFR: An Analysis from FIDELIO-DKD.
Clinical pharmacokinetics.
2022 Jul; 61(7):1013-1025. doi:
10.1007/s40262-022-01124-3. [PMID: 35508594] - Jonatan Barrera-Chimal, Casimiro Gerarduzzi, Patrick Rossignol, Frédéric Jaisser. The non-steroidal mineralocorticoid receptor antagonist finerenone is a novel therapeutic option for patients with Type 2 diabetes and chronic kidney disease.
Clinical science (London, England : 1979).
2022 06; 136(12):1005-1017. doi:
10.1042/cs20220212. [PMID: 35765983] - Rajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis M Ruilope, John Boletis, Robert Toto, Guillermo E Umpierrez, Christoph Wanner, Takashi Wada, Charlie Scott, Amer Joseph, Ike Ogbaa, Luke Roberts, Markus F Scheerer, George L Bakris. Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2022 06; 37(7):1261-1269. doi:
10.1093/ndt/gfab336. [PMID: 34850173] - Jennifer B Green, Amy K Mottl, George Bakris, Hiddo J L Heerspink, Johannes F E Mann, Janet B McGill, Masaomi Nangaku, Peter Rossing, Charlie Scott, Alain Gay, Rajiv Agarwal. Design of the COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using an UACR Endpoint study (CONFIDENCE).
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2022 Jun; ?(?):. doi:
10.1093/ndt/gfac198. [PMID: 35700142] - Gerasimos Filippatos, Bertram Pitt, Rajiv Agarwal, Dimitrios Farmakis, Luis M Ruilope, Peter Rossing, Johann Bauersachs, Robert J Mentz, Peter Kolkhof, Charlie Scott, Amer Joseph, George L Bakris, Stefan D Anker. Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial.
European journal of heart failure.
2022 Jun; 24(6):996-1005. doi:
10.1002/ejhf.2469. [PMID: 35239204] - Rajiv Agarwal, Stefan D Anker, George Bakris, Gerasimos Filippatos, Bertram Pitt, Peter Rossing, Luis Ruilope, Martin Gebel, Peter Kolkhof, Christina Nowack, Amer Joseph. Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
2022 05; 37(6):1014-1023. doi:
10.1093/ndt/gfaa294. [PMID: 33280027] - Rajesh Raj. Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease.
Current opinion in nephrology and hypertension.
2022 05; 31(3):265-271. doi:
10.1097/mnh.0000000000000785. [PMID: 35165249] - Kaitlin J Mayne, William G Herrington. In patients with type 2 diabetes and CKD, finerenone improved CV and kidney outcomes.
Annals of internal medicine.
2022 05; 175(5):JC54. doi:
10.7326/j22-0029. [PMID: 35500259] - Peter Rossing, Ellen Burgess, Rajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Pieter Gillard, Richard J MacIsaac, Julio Wainstein, Amer Joseph, Meike Brinker, Lothar Roessig, Charlie Scott, George L Bakris. Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes According to Baseline HbA1c and Insulin Use: An Analysis From the FIDELIO-DKD Study.
Diabetes care.
2022 04; 45(4):888-897. doi:
10.2337/dc21-1944. [PMID: 35061867] - Lana Gettman. New Drugs Update: Finerenone, Difelikefalin, and Avacopan.
The Senior care pharmacist.
2022 Apr; 37(4):130-138. doi:
10.4140/tcp.n.2022.130. [PMID: 35337427] - Josep Redon. New insights of cardiovascular and renal protection in diabetic chronic kidney disease with finerenone.
Cardiovascular research.
2022 03; 118(5):e36-e37. doi:
10.1093/cvr/cvac024. [PMID: 35333317] - Sebastiaan Camiel Goulooze, Nelleke Snelder, Andreas Seelmann, Andrea Horvat-Broecker, Meike Brinker, Amer Joseph, Dirk Garmann, Joerg Lippert, Thomas Eissing. Finerenone Dose-Exposure-Serum Potassium Response Analysis of FIDELIO-DKD Phase III: The Role of Dosing, Titration, and Inclusion Criteria.
Clinical pharmacokinetics.
2022 03; 61(3):451-462. doi:
10.1007/s40262-021-01083-1. [PMID: 34786651] - Paul van den Berg, Martijn Ruppert, Emir Mesic, Nelleke Snelder, Andreas Seelmann, Roland Heinig, Amer Joseph, Dirk Garmann, Joerg Lippert, Thomas Eissing. Finerenone Dose-Exposure-Response for the Primary Kidney Outcome in FIDELIO-DKD Phase III: Population Pharmacokinetic and Time-to-Event Analysis.
Clinical pharmacokinetics.
2022 03; 61(3):439-450. doi:
10.1007/s40262-021-01082-2. [PMID: 34773606] - Rajiv Agarwal, Gerasimos Filippatos, Bertram Pitt, Stefan D Anker, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Martin Gebel, Luis M Ruilope, George L Bakris. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis.
European heart journal.
2022 Feb; 43(6):474-484. doi:
10.1093/eurheartj/ehab777. [PMID: 35023547] - Carly Adamson, Pardeep S Jhund. Bringing FIDELITY to the estimate of treatment effects of finerenone in chronic kidney disease due to type 2 diabetes.
European heart journal.
2022 02; 43(6):485-487. doi:
10.1093/eurheartj/ehab827. [PMID: 34888636] - Gerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, Luis M Ruilope, Peter Rossing, George L Bakris, Christoph Tasto, Amer Joseph, Peter Kolkhof, Andrea Lage, Bertram Pitt. Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial.
Circulation.
2022 02; 145(6):437-447. doi:
10.1161/circulationaha.121.057983. [PMID: 34775784] - Thomas Wendl, Sebastian Frechen, Michael Gerisch, Roland Heinig, Thomas Eissing. Physiologically-based pharmacokinetic modeling to predict CYP3A4-mediated drug-drug interactions of finerenone.
CPT: pharmacometrics & systems pharmacology.
2022 02; 11(2):199-211. doi:
10.1002/psp4.12746. [PMID: 34783193] - V Marzolla, A Feraco, F Limana, P Kolkhof, A Armani, M Caprio. Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists.
Journal of endocrinological investigation.
2022 Jan; 45(1):215-220. doi:
10.1007/s40618-021-01635-z. [PMID: 34272678] - Peter Rossing, Rajiv Agarwal, Stefan D Anker, Gerasimos Filippatos, Bertram Pitt, Luis M Ruilope, Aslam Amod, Michel Marre, Amer Joseph, Andrea Lage, Charlie Scott, George L Bakris. Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial.
Diabetes, obesity & metabolism.
2022 01; 24(1):125-134. doi:
10.1111/dom.14558. [PMID: 34580995] - Rajiv Agarwal, Amer Joseph, Stefan D Anker, Gerasimos Filippatos, Peter Rossing, Luis M Ruilope, Bertram Pitt, Peter Kolkhof, Charlie Scott, Robert Lawatscheck, Daniel J Wilson, George L Bakris. Hyperkalemia Risk with Finerenone: Results from the FIDELIO-DKD Trial.
Journal of the American Society of Nephrology : JASN.
2022 01; 33(1):225-237. doi:
10.1681/asn.2021070942. [PMID: 34732509] - Yaning Zheng, Sheng Ma, Qiaomu Huang, Yu Fang, Hongjin Tan, Yong Chen, Cairong Li. Meta-Analysis of the Efficacy and Safety of Finerenone in Diabetic Kidney Disease.
Kidney & blood pressure research.
2022; 47(4):219-228. doi:
10.1159/000521908. [PMID: 35034019] - Giovanna Liuzzo, Massimo Volpe. FIGARO-DKD adds new evidence to the cardiovascular benefits of finerenone across the spectrum of patients with type 2 diabetes and chronic kidney disease.
European heart journal.
2021 12; 42(47):4789-4790. doi:
10.1093/eurheartj/ehab725. [PMID: 34905601] - Bertram Pitt, Gerasimos Filippatos, Rajiv Agarwal, Stefan D Anker, George L Bakris, Peter Rossing, Amer Joseph, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Luis M Ruilope. Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes.
The New England journal of medicine.
2021 12; 385(24):2252-2263. doi:
10.1056/nejmoa2110956. [PMID: 34449181] - Michał T Pochopień, David Z I Cherney, Kerstin Folkerts, Pierre Levy, Aurélie Millier, Stephen Morris, Prabir Roy-Chaudhury, Sean D Sullivan, Paul Mernagh. FINE-CKD model to evaluate economic value of finerenone in patients with chronic kidney disease and type 2 diabetes.
The American journal of managed care.
2021 12; 27(20 Suppl):S375-S382. doi:
10.37765/ajmc.2021.88808. [PMID: 34878755] - Diane S Aschenbrenner. New Type 2 Diabetes Drug AIMS to Reduce Risk of Diminished Kidney Function and Cardiovascular Complications.
The American journal of nursing.
2021 11; 121(11):22-23. doi:
10.1097/01.naj.0000798996.63395.dc. [PMID: 34673691] - Vikas S Sridhar, Hongyan Liu, David Z I Cherney. In Reply to 'Finerenone: Fiddling With Hyperkalemia?'.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2021 11; 78(5):760-761. doi:
10.1053/j.ajkd.2021.08.001. [PMID: 34400242] - Joshua Waitzman, Mark Canney, Swapnil Hiremath. Finerenone: Fiddling With Hyperkalemia?.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2021 11; 78(5):760. doi:
10.1053/j.ajkd.2021.07.006. [PMID: 34400243] - Zhangning Fu, Xiaodong Geng, Kun Chi, Chengcheng Song, Di Wu, Chao Liu, Quan Hong. Reply to letter to the editor regarding 'Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis'.
Annals of palliative medicine.
2021 10; 10(10):11242-11243. doi:
10.21037/apm-2021-07. [PMID: 34670380] - James E Frampton. Finerenone: First Approval.
Drugs.
2021 Oct; 81(15):1787-1794. doi:
10.1007/s40265-021-01599-7. [PMID: 34519996] - Mei Qiu, Li-Min Zhao. Long-term cardiorenal efficacy of finerenone in patients with chronic kidney disease and type 2 diabetes.
Annals of palliative medicine.
2021 10; 10(10):11239-11241. doi:
10.21037/apm-21-2590. [PMID: 34670379] - Achim Lother, Christoph Bode, Lutz Hein. Letter by Lother et al Regarding Article, 'Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes'.
Circulation.
2021 09; 144(11):e201. doi:
10.1161/circulationaha.121.053660. [PMID: 34516302] - Gerasimos Filippatos, Rajiv Agarwal, George Bakris, Stefan Anker. Response by Filippatos et al to Letter Regarding Article, 'Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes'.
Circulation.
2021 09; 144(11):e202-e203. doi:
10.1161/circulationaha.121.055066. [PMID: 34516303] - NULL. Finerenone (Kerendia) for chronic kidney disease.
The Medical letter on drugs and therapeutics.
2021 Aug; 63(1631):131-132. doi:
NULL. [PMID: 34544101] - Vikas S Sridhar, Hongyan Liu, David Z I Cherney. Finerenone-A New Frontier in Renin-Angiotensin-Aldosterone System Inhibition in Diabetic Kidney Disease.
American journal of kidney diseases : the official journal of the National Kidney Foundation.
2021 08; 78(2):309-311. doi:
10.1053/j.ajkd.2021.02.324. [PMID: 33753202] - Gerasimos Filippatos, George L Bakris, Bertram Pitt, Rajiv Agarwal, Peter Rossing, Luis M Ruilope, Javed Butler, Carolyn S P Lam, Peter Kolkhof, Luke Roberts, Christoph Tasto, Amer Joseph, Stefan D Anker. Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Journal of the American College of Cardiology.
2021 07; 78(2):142-152. doi:
10.1016/j.jacc.2021.04.079. [PMID: 34015478] - Zhangning Fu, Xiaodong Geng, Kun Chi, Chengcheng Song, Di Wu, Chao Liu, Quan Hong. Efficacy and safety of finerenone in patients with chronic kidney disease: a systematic review with meta-analysis and trial sequential analysis.
Annals of palliative medicine.
2021 Jul; 10(7):7428-7439. doi:
10.21037/apm-21-763. [PMID: 34353035] - Sheila A Doggrell. Finerenone - are we there yet with a non-steroidal mineralocorticoid receptor antagonist for the treatment of diabetic chronic kidney disease?.
Expert opinion on pharmacotherapy.
2021 Jul; 22(10):1253-1256. doi:
10.1080/14656566.2021.1904892. [PMID: 33764251] - Daigoro Hirohama, Mitsuhiro Nishimoto, Nobuhiro Ayuzawa, Wakako Kawarazaki, Wataru Fujii, Shigeyoshi Oba, Shigeru Shibata, Takeshi Marumo, Toshiro Fujita. Activation of Rac1-Mineralocorticoid Receptor Pathway Contributes to Renal Injury in Salt-Loaded db/db Mice.
Hypertension (Dallas, Tex. : 1979).
2021 07; 78(1):82-93. doi:
10.1161/hypertensionaha.121.17263. [PMID: 34058848] - Gabriele Rohde, Stephanie Loewen, Roland Heinig. Determination of finerenone - a novel, selective, nonsteroidal mineralocorticoid receptor antagonist - in human plasma by high-performance liquid chromatography-tandem mass spectrometry and its application to a pharmacokinetic study in venous and capillary human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2021 May; 1172(?):122643. doi:
10.1016/j.jchromb.2021.122643. [PMID: 33770684] - Ashish Verma, Ankit B Patel. Finerenone: A Non-steroidal Mineralocorticoid Receptor Blocker for Diabetic Kidney Disease.
Trends in endocrinology and metabolism: TEM.
2021 05; 32(5):261-263. doi:
10.1016/j.tem.2021.02.002. [PMID: 33637415] - C Wanner, S Nitschmann. [Finerenone in patients with chronic kidney disease and type 2 diabetes mellitus].
Der Internist.
2021 May; 62(5):577-580. doi:
10.1007/s00108-021-01028-7. [PMID: 33877367] - Donald Baumstein. Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.
The New England journal of medicine.
2021 03; 384(11):e42. doi:
NULL. [PMID: 33730465] - Arriel B Makembi, Inna Mohamadou, Pierre Galichon. Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.
The New England journal of medicine.
2021 03; 384(11):e42. doi:
NULL. [PMID: 33730466] - Nicola C Edwards, Charles J Ferro, Jonathan N Townend. Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.
The New England journal of medicine.
2021 03; 384(11):e42. doi:
NULL. [PMID: 33730467] - Morag J Young, Peter J Fuller. Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.
The New England journal of medicine.
2021 03; 384(11):e42. doi:
NULL. [PMID: 33730468] - José A Moura-Neto, Claudio Ronco. Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes.
The New England journal of medicine.
2021 03; 384(11):e42. doi:
NULL. [PMID: 33730469] - George L Bakris, Rajiv Agarwal, Gerasimos Filippatos. Finerenone and Chronic Kidney Disease Outcomes in Type 2 Diabetes. Reply.
The New England journal of medicine.
2021 03; 384(11):e42. doi:
NULL. [PMID: 33730470] - Gerasimos Filippatos, Stefan D Anker, Rajiv Agarwal, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Patrick Schloemer, Ingo Tornus, Amer Joseph, George L Bakris. Finerenone and Cardiovascular Outcomes in Patients With Chronic Kidney Disease and Type 2 Diabetes.
Circulation.
2021 02; 143(6):540-552. doi:
10.1161/circulationaha.120.051898. [PMID: 33198491] - Florian Le Billan, Julie Perrot, Elena Carceller, Simon Travers, Say Viengchareun, Peter Kolkhof, Marc Lombès, Jérôme Fagart. Antagonistic effects of finerenone and spironolactone on the aldosterone-regulated transcriptome of human kidney cells.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2021 02; 35(2):e21314. doi:
10.1096/fj.202002043rr. [PMID: 33417258] - L Lanthier, M-É Plourde, M Cauchon. [In patients with type 2 diabetes, chronic kidney disease and albuminuria, is finerenone, a selective minerocorticoid receptor antagonist, effective and safe for lowering CKD progression?].
La Revue de medecine interne.
2021 Feb; 42(2):144-145. doi:
10.1016/j.revmed.2020.12.013. [PMID: 33455835] - Murray Epstein. Aldosterone and Mineralocorticoid Receptor Signaling as Determinants of Cardiovascular and Renal Injury: From Hans Selye to the Present.
American journal of nephrology.
2021; 52(3):209-216. doi:
10.1159/000515622. [PMID: 33857953] - Karoline Droebner, Mira Pavkovic, Manuel Grundmann, Elke Hartmann, Laura Goea, Johannes Nordlohne, Jürgen Klar, Frank Eitner, Peter Kolkhof. Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis.
American journal of nephrology.
2021; 52(7):588-601. doi:
10.1159/000518254. [PMID: 34515038] - Peter Kolkhof, Elke Hartmann, Alexius Freyberger, Mira Pavkovic, Ilka Mathar, Peter Sandner, Karoline Droebner, Amer Joseph, Jörg Hüser, Frank Eitner. Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage.
American journal of nephrology.
2021; 52(8):642-652. doi:
10.1159/000516213. [PMID: 34111864] - Susan J Allison. Finerenone in chronic kidney disease.
Nature reviews. Nephrology.
2021 01; 17(1):13. doi:
10.1038/s41581-020-00371-6. [PMID: 33110253] - Carlo Patrono, Massimo Volpe. Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems.
European heart journal.
2021 01; 42(1):14-15. doi:
10.1093/eurheartj/ehaa992. [PMID: 33428718] - Andreas Lerchen, Narasimhulu Gandhamsetty, Elliot H E Farrar, Nils Winter, Johannes Platzek, Matthew N Grayson, Varinder K Aggarwal. Enantioselective Total Synthesis of (-)-Finerenone Using Asymmetric Transfer Hydrogenation.
Angewandte Chemie (International ed. in English).
2020 12; 59(51):23107-23111. doi:
10.1002/anie.202011256. [PMID: 32890415] - George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Peter Rossing, Peter Kolkhof, Christina Nowack, Patrick Schloemer, Amer Joseph, Gerasimos Filippatos. Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes.
The New England journal of medicine.
2020 Dec; 383(23):2219-2229. doi:
10.1056/nejmoa2025845. [PMID: 33264825] - Julie R Ingelfinger, Clifford J Rosen. Finerenone - Halting Relative Hyperaldosteronism in Chronic Kidney Disease.
The New England journal of medicine.
2020 12; 383(23):2285-2286. doi:
10.1056/nejme2031382. [PMID: 33095527] - Edmund Ym Chung, Marinella Ruospo, Patrizia Natale, Davide Bolignano, Sankar D Navaneethan, Suetonia C Palmer, Giovanni Fm Strippoli. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
The Cochrane database of systematic reviews.
2020 10; 10(?):CD007004. doi:
10.1002/14651858.cd007004.pub4. [PMID: 33107592] - Vincenzo Marzolla, Alessandra Feraco, Stefania Gorini, Caterina Mammi, Carmen Marrese, Valentina Mularoni, Carla Boitani, Marc Lombès, Peter Kolkhof, Maria Rosa Ciriolo, Andrea Armani, Massimiliano Caprio. The novel non-steroidal MR antagonist finerenone improves metabolic parameters in high-fat diet-fed mice and activates brown adipose tissue via AMPK-ATGL pathway.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
2020 09; 34(9):12450-12465. doi:
10.1096/fj.202000164r. [PMID: 32729974] - Nelleke Snelder, Roland Heinig, Henk-Jan Drenth, Amer Joseph, Peter Kolkhof, Jörg Lippert, Dirk Garmann, Bart Ploeger, Thomas Eissing. Population Pharmacokinetic and Exposure-Response Analysis of Finerenone: Insights Based on Phase IIb Data and Simulations to Support Dose Selection for Pivotal Trials in Type 2 Diabetes with Chronic Kidney Disease.
Clinical pharmacokinetics.
2020 03; 59(3):359-370. doi:
10.1007/s40262-019-00820-x. [PMID: 31583611] - Marta Gil-Ortega, Elena Vega-Martín, Miriam Martín-Ramos, Raquel González-Blázquez, Helena Pulido-Olmo, Gema Ruiz-Hurtado, Angela Schulz, Luis M Ruilope, Peter Kolkhof, Beatriz Somoza, Reinhold Kreutz, Maria S Fernández-Alfonso. Finerenone Reduces Intrinsic Arterial Stiffness in Munich Wistar Frömter Rats, a Genetic Model of Chronic Kidney Disease.
American journal of nephrology.
2020; 51(4):294-303. doi:
10.1159/000506275. [PMID: 32088716] - Roland Heinig, Marc Lambelet, Johannes Nagelschmitz, Abir Alatrach, Atef Halabi. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals with Mild or Moderate Hepatic Impairment.
European journal of drug metabolism and pharmacokinetics.
2019 Oct; 44(5):619-628. doi:
10.1007/s13318-019-00547-x. [PMID: 30825073] - Alessandra Ocello, Sandra La Rosa, Fulvio Fiorini, Salvatore Randone, Rosario Maccarrone, Giorgio Battaglia, Antonio Granata. [Antifibrotic renal role of mineralcorticoid receptor antagonists].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia.
2019 Jul; 36(4):. doi:
. [PMID: 31373464] - Marcel H A Muskiet, David C Wheeler, Hiddo J L Heerspink. New pharmacological strategies for protecting kidney function in type 2 diabetes.
The lancet. Diabetes & endocrinology.
2019 05; 7(5):397-412. doi:
10.1016/s2213-8587(18)30263-8. [PMID: 30579729] - Yuliya Lytvyn, Lucas C Godoy, Rosalie A Scholtes, Daniël H van Raalte, David Z Cherney. Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Current diabetes reports.
2019 01; 19(1):4. doi:
10.1007/s11892-019-1123-8. [PMID: 30673886] - George L Bakris, Rajiv Agarwal, Stefan D Anker, Bertram Pitt, Luis M Ruilope, Christina Nowack, Peter Kolkhof, Anna C Ferreira, Patrick Schloemer, Gerasimos Filippatos. Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial.
American journal of nephrology.
2019; 50(5):333-344. doi:
10.1159/000503713. [PMID: 31655812] - Luis M Ruilope, Rajiv Agarwal, Stefan D Anker, George L Bakris, Gerasimos Filippatos, Christina Nowack, Peter Kolkhof, Amer Joseph, Nicole Mentenich, Bertram Pitt. Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial.
American journal of nephrology.
2019; 50(5):345-356. doi:
10.1159/000503712. [PMID: 31665733] - Michael Gerisch, Roland Heinig, Anna Engelen, Dieter Lang, Peter Kolkhof, Martin Radtke, Johannes Platzek, Kai Lovis, Gabriele Rohde, Thomas Schwarz. Biotransformation of Finerenone, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, in Dogs, Rats, and Humans, In Vivo and In Vitro.
Drug metabolism and disposition: the biological fate of chemicals.
2018 11; 46(11):1546-1555. doi:
10.1124/dmd.118.083337. [PMID: 30171161] - Marianne Lachaux, Jonatan Barrera-Chimal, Lionel Nicol, Isabelle Rémy-Jouet, Sylvanie Renet, Anais Dumesnil, Didier Wecker, Vincent Richard, Peter Kolkhof, Frederic Jaisser, Antoine Ouvrard-Pascaud, Paul Mulder. Short- and long-term administration of the non-steroidal mineralocorticoid receptor antagonist finerenone opposes metabolic syndrome-related cardio-renal dysfunction.
Diabetes, obesity & metabolism.
2018 10; 20(10):2399-2407. doi:
10.1111/dom.13393. [PMID: 29862614] - Benjamin Bonnard, Marie Pieronne-Deperrois, Zoubir Djerada, Soumaya Elmoghrabi, Peter Kolkhof, Antoine Ouvrard-Pascaud, Paul Mulder, Frédéric Jaisser, Smail Messaoudi. Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice.
Journal of molecular and cellular cardiology.
2018 08; 121(?):124-133. doi:
10.1016/j.yjmcc.2018.06.008. [PMID: 29981797] - Jonatan Barrera-Chimal, Gabriel R Estrela, Sebastian M Lechner, Sébastien Giraud, Soumaya El Moghrabi, Shiem Kaaki, Peter Kolkhof, Thierry Hauet, Frédéric Jaisser. The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling.
Kidney international.
2018 06; 93(6):1344-1355. doi:
10.1016/j.kint.2017.12.016. [PMID: 29548765] - Hui Pei, Wei Wang, Di Zhao, Lei Wang, Guo-Hai Su, Zhuo Zhao. The use of a novel non-steroidal mineralocorticoid receptor antagonist finerenone for the treatment of chronic heart failure: A systematic review and meta-analysis.
Medicine.
2018 Apr; 97(16):e0254. doi:
10.1097/md.0000000000010254. [PMID: 29668577] - Kyriakos Dimitriadis, Constantinos Tsioufis, Panayotis Iliakis, Alexandros Kasiakogias, Ioannis Andrikou, Ioannis Leontsinis, Dimitrios Konstantinidis, Dimitrios Tousoulis. Future Anti-aldosterone Agents.
Current pharmaceutical design.
2018; 24(46):5548-5554. doi:
10.2174/1381612825666190222145116. [PMID: 30799785] - Ernesto Martínez-Martínez, Mathieu Buonafine, Ines Boukhalfa, Jaime Ibarrola, Amaya Fernández-Celis, Peter Kolkhof, Patrick Rossignol, Nicolas Girerd, Paul Mulder, Natalia López-Andrés, Antoine Ouvrard-Pascaud, Frédéric Jaisser. Aldosterone Target NGAL (Neutrophil Gelatinase-Associated Lipocalin) Is Involved in Cardiac Remodeling After Myocardial Infarction Through NFκB Pathway.
Hypertension (Dallas, Tex. : 1979).
2017 12; 70(6):1148-1156. doi:
10.1161/hypertensionaha.117.09791. [PMID: 29061727] - Lionel Lattenist, Sebastian M Lechner, Smail Messaoudi, Alan Le Mercier, Soumaya El Moghrabi, Sonia Prince, Norma A Bobadilla, Peter Kolkhof, Frédéric Jaisser, Jonatan Barrera-Chimal. Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone Protects Against Acute Kidney Injury-Mediated Chronic Kidney Disease: Role of Oxidative Stress.
Hypertension (Dallas, Tex. : 1979).
2017 05; 69(5):870-878. doi:
10.1161/hypertensionaha.116.08526. [PMID: 28320854] - Shigehiro Katayama, Daishiro Yamada, Mikihiro Nakayama, Takashi Yamada, Masafumi Myoishi, Masaharu Kato, Christina Nowack, Peter Kolkhof, Yoshimitsu Yamasaki. A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy.
Journal of diabetes and its complications.
2017 Apr; 31(4):758-765. doi:
10.1016/j.jdiacomp.2016.11.021. [PMID: 28025025] - Luis M Ruilope, Juan Tamargo. Renin-angiotensin system blockade: Finerenone.
Nephrologie & therapeutique.
2017 Apr; 13 Suppl 1(?):S47-S53. doi:
10.1016/j.nephro.2017.02.003. [PMID: 28577743] - Richard E Gilbert. Finerenone in diabetic kidney disease - So far, so good.
Journal of diabetes and its complications.
2017 04; 31(4):651-652. doi:
10.1016/j.jdiacomp.2016.12.012. [PMID: 28153675] - Peter Kolkhof, Frederic Jaisser, So-Young Kim, Gerasimos Filippatos, Christina Nowack, Bertram Pitt. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
Handbook of experimental pharmacology.
2017; 243(?):271-305. doi:
10.1007/164_2016_76. [PMID: 27830348] - Jochen Dutzmann, Robert-Jonathan Musmann, Marco Haertlé, Jan-Marcus Daniel, Kristina Sonnenschein, Andreas Schäfer, Peter Kolkhof, Johann Bauersachs, Daniel G Sedding. The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury.
PloS one.
2017; 12(9):e0184888. doi:
10.1371/journal.pone.0184888. [PMID: 28926607] - Roland Heinig, Nina Kimmeskamp-Kirschbaum, Atef Halabi, Silvia Lentini. Pharmacokinetics of the Novel Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone (BAY 94-8862) in Individuals With Renal Impairment.
Clinical pharmacology in drug development.
2016 Nov; 5(6):488-501. doi:
10.1002/cpdd.263. [PMID: 27431783] - Pingping Yang, Tianlun Huang, Gaosi Xu. The novel mineralocorticoid receptor antagonist finerenone in diabetic kidney disease: Progress and challenges.
Metabolism: clinical and experimental.
2016 09; 65(9):1342-9. doi:
10.1016/j.metabol.2016.06.001. [PMID: 27506741] - Duygu Batu Demir, Mark E Cooper. New strategies to tackle diabetic kidney disease.
Current opinion in nephrology and hypertension.
2016 07; 25(4):348-54. doi:
10.1097/mnh.0000000000000234. [PMID: 27138228] - Naoki Sato, Masayoshi Ajioka, Takahisa Yamada, Masaharu Kato, Masafumi Myoishi, Takashi Yamada, So-Young Kim, Christina Nowack, Peter Kolkhof, Tsuyoshi Shiga. A Randomized Controlled Study of Finerenone vs. Eplerenone in Japanese Patients With Worsening Chronic Heart Failure and Diabetes and/or Chronic Kidney Disease.
Circulation journal : official journal of the Japanese Circulation Society.
2016 Apr; 80(5):1113-22. doi:
10.1253/circj.cj-16-0122. [PMID: 27074824] - Hermann Haller, Anna Bertram, Klaus Stahl, Jan Menne. Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?.
Current hypertension reports.
2016 Apr; 18(5):41. doi:
10.1007/s11906-016-0649-2. [PMID: 27115525] - Silvia Lentini, Roland Heinig, Nina Kimmeskamp-Kirschbaum, Georg Wensing. Pharmacokinetics, safety and tolerability of the novel, selective mineralocorticoid receptor antagonist finerenone - results from first-in-man and relative bioavailability studies.
Fundamental & clinical pharmacology.
2016 Apr; 30(2):172-84. doi:
10.1111/fcp.12170. [PMID: 26604072] - Peter Bramlage, Stephanie L Swift, Martin Thoenes, Joan Minguet, Carmen Ferrero, Roland E Schmieder. Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease.
European journal of heart failure.
2016 Jan; 18(1):28-37. doi:
10.1002/ejhf.444. [PMID: 26634965] - Larbi Amazit, Florian Le Billan, Peter Kolkhof, Khadija Lamribet, Say Viengchareun, Michel R Fay, Junaid A Khan, Alexander Hillisch, Marc Lombès, Marie-Edith Rafestin-Oblin, Jérôme Fagart. Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1.
The Journal of biological chemistry.
2015 Sep; 290(36):21876-89. doi:
10.1074/jbc.m115.657957. [PMID: 26203193] - George L Bakris, Rajiv Agarwal, Juliana C Chan, Mark E Cooper, Ron T Gansevoort, Hermann Haller, Giuseppe Remuzzi, Peter Rossing, Roland E Schmieder, Christina Nowack, Peter Kolkhof, Amer Joseph, Alexander Pieper, Nina Kimmeskamp-Kirschbaum, Luis M Ruilope. Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial.
JAMA.
2015 Sep; 314(9):884-94. doi:
10.1001/jama.2015.10081. [PMID: 26325557] - Bertram Pitt, Stefan D Anker, Michael Böhm, Mihai Gheorghiade, Lars Køber, Henry Krum, Aldo P Maggioni, Piotr Ponikowski, Adriaan A Voors, Faiez Zannad, Christina Nowack, So-Young Kim, Alexander Pieper, Nina Kimmeskamp-Kirschbaum, Gerasimos Filippatos. Rationale and design of MinerAlocorticoid Receptor antagonist Tolerability Study-Heart Failure (ARTS-HF): a randomized study of finerenone vs. eplerenone in patients who have worsening chronic heart failure with diabetes and/or chronic kidney disease.
European journal of heart failure.
2015 Feb; 17(2):224-32. doi:
10.1002/ejhf.218. [PMID: 25678098]
